1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cannara Biotech Inc.

Cannara Biotech Inc.

LOVE.V
Cannara Biotech Inc.CA flagToronto Stock Exchange Ventures
1.89
CAD
+0.11
- -
181.03MMarket Cap
Cannara Biotech Inc.
LOVE.V
(Toronto Stock Exchange Ventures)

Recent

price

1.89

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.03
0.04
0.22
0.41
0.64
0.91
1.18
1.2
Revenue per Share
-0.03
-0.2
-0.17
-0.02
0.03
0.08
0.07
0.14
0.11
Basic EPS, GAAP
-0.23
-0.5
-0.26
-0.43
-0.25
-0.04
0.04
0.15
0.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.2
0.66
0.44
0.71
0.65
0.78
0.84
0.99
1.14
Book Value per Share
0.21
0.81
0.54
0.84
0.76
0.89
0.98
1.12
1.28
Tangible Book Value per Share
69
61
71
77
88
89
90
91
94
Basic Weighted Avg Shares
- -
2
3
17
36
57
82
107
113
Sales/Revenue/Turnover
- -
-487.52
-467.66
1.76
13.88
20.99
9.84
20.31
15.74
Operating Margin (%)
- -
1
3
3
4
5
6
7
6
Depreciation Expense
-2
-12
-12
-2
2
7
6
13
10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
27.74
33.15
Effective Tax Rate (%)
- -
-587.28
-489.35
-8.98
6.43
12.13
7.88
12.2
9
Profit Margin (%)
12
23
7
12
29
31
40
48
61
Working Capital
13
13
12
20
46
40
39
28
25
LT Debt
15
50
38
64
67
80
88
102
120
Total Equity
- -
- -
- -
- -
4.96
9.73
- -
10.58
7.64
Return on Invested Capital (%)
- -
- -
- -
- -
5.63
10.4
- -
12.37
9
Return on Capital (%)
- -
-45.41
-34.78
-3.56
4.13
10.98
8.88
15.8
10.99
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'25
Nov'26
Feb'26
ST Debt
13
9
9
LT Borrowings
28
26
25
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
95
96
Market Capitalization
163
155
177

Working Capital

FRC

•

in mil. unless spec.
Aug'25
Nov'26
Feb'26
Total Current Assets
82
85
91
Cash, Cash Equivalents & STI
14
17
22
Accounts Receivable, Net
14
15
12
Inventories
51
52
54
Total Current Liabilities
34
31
30
Payables & Accruals
21
22
21
ST Debt
13
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
23.44%
16.22%
Free Cash Flow
- -
21.04%
324.86%
Net Income, GAAP
- -
-8.31%
103.09%
Sales/Revenue/Turnover
- -
162.3%
31.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
20
20
23
82
2025
25
27
27
28
107
2026
30
27
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.04
0.02
- -
0.07
2025
0.03
0.04
0.05
- -
0.14
2026
0.01
0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Shionogi & Co., Ltd. (SGIOY)
Duopharma Biotech Berhad (7148.KL)
Orchid Pharma Limited (ORCHPHARMA.BO)
Verano Holdings Corp. (VRNO.NE)
Emergent Health Corp (EMGE)
Standard Chem & Pharm Co. Ltd. (1720.TW)
Business
Cannara Biotech Inc. (TSXV:LOVE) is a vertically integrated Canadian producer of premium-grade cannabis and cannabis-derivative products for recreational and medical markets. The company cultivates, processes, and sells a broad portfolio of products under its three flagship brands—TRIBAL, nugz, and ORCHID CBD—including dried flower in small and large formats; pre-rolls; live resin vape cartridges; live resin full spectrum extracts; cannabis oils; hash; rosin; and accessories such as hash wraps, all-in-one vapes, and dry flower vaporizers. Cannara Biotech operates state-of-the-art indoor cultivation facilities in Quebec spanning over 1.6 million square feet at its Farnham and Valleyfield sites, enabling scalable production targeting up to 100,000 kg of annualized output; it distributes through wholesalers and online merchandisers primarily in Quebec, Ontario, Saskatchewan, British Columbia, with expansion into Alberta. Founded in 2017 and headquartered in Saint-Laurent, Quebec, the company also maintains a real estate operations segment alongside its core cannabis activities. Recent developments include the August 2025 amendment and $10 million upsize of its BMO credit facility to fund Phase 1 post-harvest expansion at Valleyfield, featuring advanced hang-drying, freezing, trimming, packaging, and butane extraction upgrades; the completion of a $5.45 million strategic sale of non-core Valleyfield land and building in August 2025 to reduce term loan debt; securing five key vape cartridge listings in Quebec in July 2025 including live rosin variants; a debt-to-equity conversion and DTC eligibility in October 2025 to enhance U.S. investor access and balance sheet strength; and the appointment of Justin Cohen to its board of directors in March 2025.